A rteriovenous malformations (AVMs) of the brain are vascular lesions that shunt arterial blood directly into a low-resistance system of draining veins without an intervening normal capillary bed. The prevalence of AVMs ranges from 15 to 18 per 100,000 adults, 2 with an approximate detection rate of 1 per 100,000 adults per year, 6 which classifies these vascular malformations as rare diseases. The most common presentation of AVMs is intracerebral hemorrhage, which typically occurs in patients 20-40 years of age and affects approximately 50% of individuals with AVM.
The etiology of AVMs is still poorly understood. Some data have suggested a role for a genetic component in the development of AVM. 18, 19 Of note, AVMs are a hallmark of hereditary hemorrhagic telangiectasia. This condition is caused by mutations in the ENG and ACVRL1 genes and characterized by hereditary AVMs involving different organ systems, including the CNS. 32 In addition, several case-control studies have found associations of singlenucleotide polymorphisms (SNPs) in various candidate genes with susceptibility to AVMs, the risk for hemorrhage, or both. 16, 17, 23, 28, 36, 41 NOTCH4 is a member of the NOTCH gene family. Its members govern cellular differentiation and cell-fate determination and control the normal development of vessels and proper arteriovenous specification. NOTCH receptors and their ligands are expressed in arterial walls but not in those of the venous system, 20 and this arterial expression is both necessary and sufficient to induce that of ephrin-B2, considered to be a specific marker of arterial differentiation. The NOTCH4 gene is located on chromosome 6p21.32. Its 30 exons (Fig. 1A ) encode a 2003-amino-acids-long, single-pass transmembrane protein with ankyrin repeats in the intracellular and epidermal growth factor (EGF) repeats in the extracellular NOTCH4 domain. NOTCH4 binds to 2 different ligands: Delta and Serrate/ Jagged. 9, 22 Ligand binding to the extracellular domain results in the proteolytic release of the intracellular domain and its translocation to the cell nucleus, which, in turn, initiates the expression of primary target genes belonging to the HES and HER gene families, which are involved in vascular development and proper arteriovenous differentiation. 5, 13, 37 Several studies have already suggested a role for NOTCH signaling in AVM formation and progression to hemorrhage. Recent work with a mouse model with transgenic expression of constitutively active Notch4 in endothelial cells has demonstrated that upregulation of Notch4 signaling causes vascular abnormalities very similar to those observed in AVM. [25] [26] [27] Conversely, normalization of the elevated Notch4 levels resulted in decreased AVM vessel size. 25 In addition, genome-wide expression profiling in peripheral blood revealed differential expression of some genes involved in NOTCH signaling in patients with ruptured and unruptured AVMs compared with healthy controls. 42 Last, NOTCH4 activation in endothelial and smooth-muscle cells of human AVM was very recently demonstrated by immunohistochemistry. 44 Taken together, these studies suggest a role for NOTCH4 in the formation and phenotypes of AVMs. This observation prompted us to conduct a case-control study to investigate possible associations of genetic polymorphisms in the NOTCH4 gene with disease susceptibility and relevant clinical features.
The present study investigated whether 10 SNPs in the NOTCH4 gene in 153 AVM patients and 192 controls were potentially associated with AVM formation and other clinical findings. Specific NOTCH4 SNP haplotypes were found to be associated with AVM susceptibility, and several single genetic markers could be linked to hemorrhagic (and epileptic) presentation. These data provide support for a role of the NOTCH4 gene in the formation and progression of AVM. They also suggest that NOTCH4 genetic variants may have potential for use as new clinical biomarkers.
Methods

Study Cohort
In total, this study included 153 white patients with AVMs, 50% of whom were male. The median age at treatment was 39 ± 15.5 years (mean 41, range 9-70 years). All patients had undergone diagnostic digital subtraction angiography. 34 In 108 patients who underwent surgery, the diagnosis of AVM was confirmed histologically. Clinical and angiographic data were available for 129 patients ( Table 1) .
The control group consisted of 192 white healthy blood donors (96 men and 96 women), with a median age of 27 ± 5.5 years (mean 25, range 18-60 years). Before any blood donation, all candidate donors underwent a thorough clinical examination and were asked to fill out an extensive questionnaire about their own and family medical histories. In case of any medical conditions or signs and symptoms pointing to any significant disease (including recurrent headaches or epilepsy), cardiovascular risk factors, or hereditary diseases in either the individual or her or his family, the candidate donor was excluded from blood donation.
The study was approved by the ethics committee of the University of Bonn Medical Center. Informed consent was obtained from all patients and controls according to the Declaration of Helsinki.
Selection and Genotyping of NOTCH4 Gene SNPs
Ten ( High-molecular-weight genomic DNA was isolated from leukocytes with a salting-out procedure. 24 All 10 polymorphisms were analyzed after PCR amplification, followed by restriction-enzyme digest analysis for 2 SNPs and direct sequencing of both DNA strands with the BigDye Terminator Cycle Sequencing V1.1 Ready Reaction kit and an automated ABI-3100 DNA sequencer (Applied Biosystems) for the remaining 8 SNPs. Primers were designed with the Primer3 software version 0.4.0 (Whitehead Institute for Biomedical Research). Details on the primers, 38 restriction enzymes, and PCR conditions used are available on request.
Haplotype Analysis
Recent work has suggested that a multimarker (haplotype) analysis may improve genotyping efficiency and refine the association signal. 11 We therefore performed an explorative haplotype study and calculated all possible haplotypes consisting of up to 4 SNPs. This analysis re-sulted in calculated haplotype frequencies of 1% in some cases. This low haplotype frequency, along with the limited number of patients and controls in this study, precluded further analysis of more complex haplotypes.
Genotype-Phenotype Correlations
Because the data from the association study suggested a link between NOTCH4 gene variants and AVM biology, we also looked for possible correlations between NOTCH4 SNP genotypes and clinical parameters. Hence, we investigated all SNPs as potential predictors of hemorrhagic presentation or presentation with epilepsy.
Biostatistical Analysis
Hardy-Weinberg equilibrium and linkage disequilibrium were estimated with Haploview software V4.0. 
Results
Clinical and Angiographic Data
Relevant clinical and demographic data were retrieved for 129 patients and included the following parameters: clinical presentation (bleeding, epilepsy, or other), maximum AVM diameter, presence or absence of AVM-associated aneurysms or deep venous drainage, and AVM location and Spetzler-Martin grade 34 ( Table 1) . Sixty-four (50%) patients had a history of AVM bleeding, and symptomatic epilepsy was recorded in 56 (43%) patients. One hundred eight (84%) patients had surgery for AVM, 15 of whom had undergone AVM embolization before the operation. Five patients underwent only radiosurgery, and 16 patients underwent a combination of radiosurgery and embolization. Nineteen of the patients had Spetzler-Martin Grade I AVMs, 59 Grade II, 43 Grade III, 7 Grade IV, and 1 Grade V.
NOTCH4 SNP Haplotypes Are Associated With Susceptibility to AVMs
In total, 153 AVM patients and 192 healthy individuals were genotyped for 10 different NOTCH4 SNPs. To determine if any of the NOTCH4 SNPs were associated with susceptibility to the disease, we performed a case-control analysis comparing the SNP genotype distributions in the patient and control groups. No statistically significant correlations were detected, and only a trend for an association was observed for the rs3134798 SNP (p = 0.1).
Next, as outlined in Methods, calculated haplotype frequencies were compared between the 2 groups. After Bonferroni correction for multiple testing, this analysis revealed that 11 haplotypes were significantly more common among the AVM patients (uncorrected p ≤ 1 × 10 -15 ), suggesting that these haplotypes were associated with greater susceptibility to AVM. Interestingly, the haplotypes did not map randomly to the NOTCH4 gene. Rather, all of them contained at least 2 of 3 SNPs (rs1109771 [A/G], rs415929 [A/G], and rs715299 [A/C]), which were all localized to the region of the gene coding for the Ca 2+ -binding part of the EGF-like domain of the NOTCH4 protein (Fig. 1B and C) .
Genotype-Phenotype Correlations
Univariate analysis indicated that the homozygous rs443198_TT and rs915895_AA genotypes were statistically significantly associated with a greater risk for hemorrhage than their heterozygous reference genotypes (Table  2) . Univariate analysis also revealed that clinical parameters that were significantly correlated with AVM bleeds in the present series included an AVM size of < 3 cm and no epilepsy at presentation. A multivariate stepwise regression analysis including rs443198_TT, rs915895_AA, AVM size < 3 cm, and no epilepsy at presentation as covariates confirmed rs443198_TT and no epilepsy at pre- sentation as independent variables significantly associated with hemorrhage (Table 3) . Statistically significant predictors of epileptic presentation included the rs1109771_GG genotype, AVM size ≥ 3 cm, nonhemorrhagic presentation, and supratentorial versus infratentorial location (p < 0.001) ( Table 4) . When we performed multivariate stepwise regression analysis with rs1109771_GG, AVM size ≥ 3 cm, and presentation as covariates, only nonhemorrhagic presentation remained an independent predictor for epilepsy (Table 5) .
Following the same rationale as outlined above for the susceptibility study, we also performed explorative haplotype analyses to look for genotype-phenotype correlations of NOTCH4 haplotypes with clinical presentation. Because of the smaller sample size (129 patients versus a total of 345 cases and controls in the susceptibility study), we restricted this analysis to haplotypes consisting of up to 3 SNPs. Several statistically significant associations were observed, none of which remained significant after correction for multiple testing.
Discussion
Brain AVMs represent an important cause for neurological impairment due to intracerebral bleeding or sometimes symptomatic epilepsy in young adults. 32, 33 Prevention of AVM hemorrhages (or rehemorrhages) remains the primary goal of AVM treatment, and clinical decision making often consists of balancing the presumed risk of (further) bleeds against the risks of AVM treatment. A better understanding of the biology of the disease could lead to the identification of novel biomarkers for the prediction of the patients' future clinical course (i.e., for hemorrhage prediction) or even ultimately result in the development of new treatment strategies. Studying the genetic factors involved in a certain disease may identify genes and biological mechanisms underlying its pathogenesis. Following this rationale, we and others have investigated genetic polymorphisms of candidate genes for possible associations with susceptibility to AVMs and with specific clinical features of the disease such as hemorrhagic presentation. 17, 18, 23, 28, 32, 35 In the present work, we tested whether SNPs in the NOTCH4 gene are potential genetic risk factors for the development of AVMs, AVM bleeds, or AVM-associated epilepsy. Our results suggest a role of the NOTCH4 gene in AVM biology. First, they suggest an association between NOTCH4 gene SNPs and increased susceptibility to AVMs. Second, our results from the multivariate analysis also linked certain NOTCH4 gene variants to key clinical features such as hemorrhage. We note that NOTCH4 is a highly plausible candidate AVM gene. Murphy et al. have shown that expression of constitutively active Notch4 leads to the development of AVMs in mice. 26, 27 Moreover, normalizing Notch4 signaling by turning off constitutive expression of the Notch4 gene in mice reduces AVM vessel size. 25 Using immunohistochemistry, ZhuGe and colleagues have recently shown upregulation and activation of NOTCH4 in endothelial and smooth-muscle cells in human AVMs. 44 A number of studies have investigated genetic polymorphisms for possible associations with AVM development; however, many of these investigations have focused on genes with roles in inflammatory pathways. 1, 8, 12, 17, 28 In contrast, genes involved in angiogenesis have so far received surprisingly little attention. 30, 41 Genes with a known role in angiogenesis that have been reported to be associated with AVM formation include ALK1, 29, 32 ANGPTL4, 23 and VEGF. 7 Interestingly, the VEGF and ALK1 pathways involved in vascular development interact with the NOTCH pathway. 21, 31 Most recently, Zhang and coworkers proposed an AVM pathogenesis pathway in which NOTCH signaling is located downstream of AVM-causative genes like ALK1 and VEGF. 43 We did not detect statistically significant correlations between single NOTCH4 SNPs and AVM formation, which may be well explained by the relatively small size of our patient cohort. However, it has been shown that haplotype-based tagging can outperform single-marker tests and can help to both increase the association efficiency and refine the association signal.
11 Therefore, we also investigated whether calculated haplotypes consisting of up to 4 SNPs were possibly associated with AVM. We note that this approach was somewhat exploratory; however, this analysis linked specific haplotypes to an increased risk for developing AVM (Fig. 1B and C) . In addition, we did find a single-marker association between the NOTCH4 rs443198_TT SNP genotype and a key clinical feature, that is, presentation with hemorrhage. Of note, in the multivariate regression analysis, rs443198_TT remained a statistically significant predictor of a hemorrhagic presentation. Interestingly, rs443198_TT has not been previously reported to be associated with hemorrhage in other diseases, an observation that points to a possible specific involvement of this NOTCH4 SNP in AVM-associated hemorrhage.
The NOTCH4 SNPs linked to AVM biology in our analyses did not map randomly to the gene, supporting the contention that our results are not chance findings. All of the haplotypes linked to an increased risk for AVM formation contained at least 2 of 3 SNPs (rs715299, rs415929, and rs110977), all of which map to the Ca 2+ -binding sites of the NOTCH4 EGF-like receptor domain (Fig. 1B and  C) , which is known to play an important role in receptorligand interactions. Therefore, any genetic or structural variance in this region might have functional consequences. The rs443198 SNP, which is linked to clinical presentation of hemorrhage, maps relatively closely to rs715299 and was also present in several haplotypes associated with AVM formation. rs443198 is located in the coding part of exon 3 and is predicted to result in an (albeit synonymous) amino acid change or in an alternative splice site. 
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Limitation of the Study and Further Investigations
Our study has significant limitations. First, the small sample size in our study could have led to false-positive associations and confounder effects. Second, our conclusions are based in part on calculated haplotype frequencies. This approach was somewhat exploratory, the results of which may not be as robust as the results of a casecontrolled comparison of SNP genotype distributions. The results of our study suggest but do not provide conclusive evidence for a significant link between NOTCH4 and AVM disease. Nevertheless, we believe that the data presented here, along with previous preclinical investigations in animal models, support a role for NOTCH4 in the formation and presentation of AVM. We propose that validation of our results via a confirmatory analysis of an independent and, if possible, larger AVM patient cohort will be a crucial next step.
Conclusions
Our results point to a role of the NOTCH4 gene in the formation and progression of AVM. Our data suggest that some NOTCH4 gene SNPs are linked to the risk for developing an AVM and also to AVM clinical parameters such as hemorrhage and epilepsy. We note the limitations of our study, most notably its small sample size, which may allow for differences in the cohort substructure to go undetected, leading to false-positive associations or confounder effects. Nevertheless, we believe that our data clearly warrant follow-up studies and, if possible, confirmation in a larger patient cohort.
